Jiangsu Hengrui Medicine Co., Ltd, a leading pharmaceutical company based in China and listed on the Shanghai Stock Exchange (SHA: 600276), has announced the resignation of two of its key executives, Ms. Jiang Sumei and Mr. Wang Hongsen, both of whom held the position of Deputy General Manager. Both executives have cited personal reasons for their departure.
Ms. Jiang Sumei, at the age of 60, has had an extensive tenure with Hengrui Medicine since 2000, taking on various roles including Head of the Quality Inspection Department, Quality Director, Deputy General Manager, Executive Deputy General Manager, and Director. Her experience also extends to managing positions at Suncadia Medicine across multiple provinces and cities, as well as General Manager roles at Shanghai Hengrui Pharmaceuticals Co., Ltd. and Guangdong Hengrui Medicine Co. Ltd. In 2023, her total pre-tax compensation at Hengrui Medicine was reported to be RMB 2.472 million.
Mr. Wang Hongsen, 54 years old, joined Hengrui Medicine in 1991 as a technician in the company’s research institute and workshop, serving in this capacity until the end of 1994. From 1995 to 2009, he held the position of Minister and Director of the material supply department. His career progressed to Director of the raw materials branch from 2010 to 2015, followed by his appointment as the Manufacturing Deputy General Manager in October 2015. In July 2020, he was elevated to the role of Deputy General Manager. Wang Hongsen has also served as General Manager of Chengdu Suncadia Medicine Co., Ltd. and Chengdu Xinyue Pharmaceutical Co., Ltd. His total pre-tax salary for the year 2023 at Hengrui Pharmaceutical was RMB 2.1446 million.- Flcube.com
